TRI Monthly SEMINAR SERIES
The TRI events team are currently requesting nominations for the 2018/2018 TRI Monthly Seminar Series.
The TRI Monthly Seminar series aims to attract speakers of international renown by identifying international conferences held in Australia and offering to cover the domestic travel and accomodation expenses, of key note speakers, to present at TRI.
TRI based researchers, if you'd like to nominate a speaker, please contact them to ascertain their availability. If the speaker would like to present at TRI, please complete the online form and submit to: [email protected]
2018 Schedule
|
Date & Time |
Time | Featured Speaker | TRI Host | Details |
| Tuesday 11 December | ||||
| Tuesday 4 December | ||||
| Tuesday 27 November | ||||
| Tuesday 16 October | ||||
| Tuesday 9 October | ||||
| Tuesday 2 October | ||||
| Tuesday 4 September | 5:00pm - 6:00pm |
Dr Herb Kressel, Harvard |
Dr Carolyn Mountford | Title: 'Use of Gadolinium in MRI' |
| Tuesday 21 August | 12:00 - 1:00pm | Clifton David Fuller, Texas University, Precision Radiotherapy | Dr Graham Galloway | |
| Tuesday 15 May | 12.00 - 1.00pm |
Professor Felipe Prosper MD,PhD Head of the Hematology and Cell Therapy Department University of Navarra, Spain |
QUT, ihbi |
Title: "Harnessing Epigenetics to improve diagnoses and treatment of cancer." Professor Prosper graduated from the University of Navarra in 1989 and after his residency and PhD he completed his fellowship and postdoctoral training at the University of Minnesota. Relocated to the Clinica Universidad de Navarra in 2001, he was responsible for the development of the cell therapy program where he became the Head of Hematology and Cell Therapy in 2003 and Director of the programs of Hematology and Cell Therapy at the center for Applied Medical Research at the University of Navarra in 2012. Prosper has published more than 280 peer review articles in top journals including New England Journal of Medicine, Nature Genetics or Blood among others, with an h-factor of 53 and over 9890 citations. |
|
Tuesday 20 March |
12.00 - 1.00pm |
Dr Cameron Turtle Fred Hutch Cancer Centre Seattle, Clinical Trials Immunotherapy |
Dr Kristen Radford, Mater |
Dr. Turtle is currently an Attending Physician on the Fred Hutch Bone Marrow Transplant Program and the Immunotherapy Service at the Seattle Cancer Care Alliance (SCCA), a cancer treatment center that unites doctors from Fred Hutch, University of Washington Medicine and Seattle Children’s Hospital. |
| Wednesday 28 February | 12.00 - 1.00pm |
Dr Boris Holzapfel Dr. med. at Ludwigs-Maximilians University of Munich, Bavaria, Germany |
Distinguished Professor Dietmar W. Hutmacher |
Title: 'Patient Specific Design, Planning and Surgery of Complex Orthopaedic Tumor Cases' Dr Boris Holzapfel is an orthopaedic oncologist and surgeon with outstanding experience in the treatment of primary and secondary tumours of the musculoskeletal system. In this context he is trying to implement bone tissue engineering approaches into surgical therapy concepts of these tumours. His translational research is focused on the biology of bone and soft tissue sarcomas and on the molecular mechanisms that lead to the development of bone metastases. By combining his knowledge about bone tissue engineering and tumour biology, he established several novel xenograft models of bone metastasis that make it possible to analyse the species-specific mechanisms of human cancer cell osteotropism. |
2017 Speaker Archive
|
Date & Time |
Time | Featured Speaker | TRI Host | Title & Abstract |
|
30 May 2017 *Please note date change |
12.00 - 1.00pm |
Prof Alan Mackay-Sim, 2017 Australian of the Year |
Dr Alexandre Cristino |
Hereditary Spastic Paraplegia: from stem cells to drug discovery |
|
6 June 2017 |
12.00 - 1.00pm |
A/Prof Michael Samuel, Head Tumour Microenvironment Lab, Centre for Cancer Biology, SA Pathology & the University of South Australia |
Prof Rik Thompson |
Biochemical and biomechanical inter-relationships in cancer and wound healing |
| 20 June 2017 | 12.00 - 1.00pm | Prof Cornellia Weyand, Medicine - Immunology and Rheumatology, Stanford | Prof Ranjeny Thomas | Immunometabolic Signatures in Autoimmunity |
| 4 July 2017 | 12.00 - 1.00pm | Professor Nick Graves, Health Economist, QUT | Professor Gerald Holtmann | Are we overpowering intervention studies? P-values, Clinical Trials and Waste in Research |
| 25 July 2017 | 12.00 - 1.00pm | Dr Jonathan Sherlock, Kennedy Institute of Rhuematology, University of Oxford | Prof Ranjeny Thomas | Immunological pathways implicated in autoimmune diseases |
| 8 August | 12.00 - 1.00pm | Professor Carl Walkley, St Vincent's Institute of Medical Research Melbourne | Mater Research |
Title: Rewriting the transcriptome: ADAR1 mediated A-to-I RNA editing One of the most prevalent forms of post-transcriptional RNA modification is the conversion of adenosine bases to inosine (A-to-I), mediated by the ADAR family of enzymes. A-to-I editing is a widespread feature of the transcriptome, with estimates ranging from tens of thousands in mice to millions of A-to-I editing events in humans and primates. We have used in vivo haematology as a system to understand how RNA editing by ADAR1 regulates the transcriptome, and how this interfaces with the innate immune system and enables discrimination of self and non-self nucleic acids. |
| 5 September | 9am-5pm | Imagine | Professor Carolyn Mountford |
Imagine 2017 |
| 3 October 2017 | 12.00 - 1.00pm | Prof Roger Daly, Molecular Biology, Monash University | Prof Brian Gabrielle | Protein kinase signalling networks in human cancer |
| 19 October 2017 | 12.00 - 1.00pm | Prof Brian Gabrielle | World Melanoma Congress |
